StockNews.com Begins Coverage on Trinity Biotech (NASDAQ:TRIB)

StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report issued to clients and investors on Saturday. The firm set a “buy” rating on the stock.

Trinity Biotech Stock Performance

Shares of TRIB opened at $3.29 on Friday. The business has a 50-day moving average of $2.08 and a 200 day moving average of $2.15. Trinity Biotech has a fifty-two week low of $1.49 and a fifty-two week high of $5.25. The firm has a market cap of $25.08 million, a P/E ratio of -1.18 and a beta of 1.31.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings data on Thursday, May 23rd. The company reported ($0.37) earnings per share for the quarter. The company had revenue of $14.70 million during the quarter. As a group, research analysts predict that Trinity Biotech will post -2.17 earnings per share for the current fiscal year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.